Specify a stock or a cryptocurrency in the search bar to get a summary
Pacira BioSciences, Inc.
PCRXPacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Address: 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609
Analytics
WallStreet Target Price
24.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PCRX
Dividend Analytics PCRX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PCRX
Stock Valuation PCRX
Financials PCRX
Results | 2019 | Dynamics |